Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer.

Overview of attention for article published in Cancer Discovery, May 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

So far, Altmetric has seen 71 X posts from 52 X users, with an upper bound of 393,025 followers.

@NCICancerBio A3: I've been excited to see research that is allowing us to have a better understanding of the ovarian cancer microenvironment. A few recent papers: https://t.co/iBweQkzOB1 https://t.co/4ZhkmllYNF

RT @DrBaileeSliker: At the #AACR23 session on ovarian cancer? ICYMI: Tumor-derived Lysophosphatidic Acid Blunts Protective Type-I #Interfer…

RT @DrBaileeSliker: At the #AACR23 session on ovarian cancer? ICYMI: Tumor-derived Lysophosphatidic Acid Blunts Protective Type-I #Interfer…

At the #AACR23 session on ovarian cancer? ICYMI: Tumor-derived Lysophosphatidic Acid Blunts Protective Type-I #Interferon Responses in #OvarianCancer @JCubRuiz @WeillCornell #immunotherapy @CD_AACR https://t.co/V2WY0VjvK8 https://t.co/KoLhGViz7S

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 67 additional X posts.